¼ø¼ö ¾ËÃ÷ÇÏÀ̸Ӻ´ Ä¡¸Å ȯÀÚ±º°ú È¥ÇÕ¼º Ä¡¸Å ȯÀÚ±º¿¡¼ 12°³¿ù°£ÀÇ µµ³×ÆäÁú(Donepezil) Åõ¿©¿¡ µû¸¥ Ä¡·á ¼ºÀûÀÇ ºñ±³ Æò°¡
Comparative Assessment of Clinical Efficacy after 12-Month Clinical Trial of Donepezil between the Patients with Pure Alzheimer¡¯s Disease and Mixed Dementia
³ëÀÎÁ¤½ÅÀÇÇÐ 2010³â 14±Ç 1È£ p.58 ~ p.64
°È¿½Å(Kang Hyo-Shin) - »ï¼º¼¿ïº´¿ø »ï¼º»ý¸í°úÇבּ¸¼Ò ÀÓ»óÀÇÇм¾ÅÍ
¾ÈÀμ÷(Ahn Inn-Sook) - »ï¼º¼¿ïº´¿ø »ï¼º»ý¸í°úÇבּ¸¼Ò ÀÓ»óÀÇÇм¾ÅÍ
À±ÁöÇý(Yun Ji-Hae) - »ï¼º¼¿ïº´¿ø »ï¼º»ý¸í°úÇבּ¸¼Ò ÀÓ»óÀÇÇм¾ÅÍ
¹®À¯Áø(Mooon Yu-Jin) - »ï¼º¼¿ïº´¿ø »ï¼º»ý¸í°úÇבּ¸¼Ò ÀÓ»óÀÇÇм¾ÅÍ
ȲÅ¿µ(Hwang Tae-Young) - ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø Á¤½Å°úÇб³½Ç
ÀÌ¿µ¹Î(Lee Young-Min) - ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø Á¤½Å°úÇб³½Ç
±èÇý¶õ(Kim Hye-Ran) - ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø Á¤½Å°úÇб³½Ç
Á¤Àç¿ø(Chung Jae-Won) - ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼º¼¿ïº´¿ø Á¤½Å°úÇб³½Ç
±èµµ°ü(Kim Doh-Kwan) - »ï¼º¼¿ïº´¿ø »ï¼º»ý¸í°úÇבּ¸¼Ò ÀÓ»óÀÇÇм¾ÅÍ
Abstract
Objectives: The purpose of this study was to compare the efficacy of donepezil treatment between patients with pure Alzheimer¡¯s
disease (AD) and Mixed dementia (MD) during a 12-month trial.
Methods: A total of 139 patients were recruited for this 52-week study. The effect of donepezil on cognitive function was measured
using Alzheimer¡¯s Disease Assessment Scale-cognitive subscale-preliminary Korean version (ADAS-cog-K). Patients¡¯ activities of
daily living using the Seoul-Instrumental Activities of Daily Living (S-IADL) and Seoul-Activities of Daily Living (S-ADL)£»behavioral
symptoms using the Korean version Neuropsychiatric Inventory (K-NPI) were measured at baseline, 13-weeks, 26-weeks,
39-weeks and 52-weeks. We defined the responsive patients to donepezil at those who showed a cognitive improvement or no change
during the first six-month clinical trial.
Results: 84 pure AD patients and 34 MD patients were available for intent-to-treat (ITT) last observation carried forward (LOCF)
analysis. There was no significant difference between two groups in mean change from baseline in the total ADAS-cog-k, S-ADL, SIADL
and K-NPI scores at 52-week. Based on the operational criteria, 60.7% of pure AD patients and 58.8% of MD patients were
responders to donepezil.
Conclusion: MD patients had similar levels of efficacy with pure AD patients and donepezil was well tolerated in both groups.
These results suggest that donepezil is an effective and well-tolerated treatment for MD patients as well as for pure AD patients.
Å°¿öµå
Alzheimer¡¯s Disease¡¤Mixed Dementia¡¤Donepezil¡¤Treatment response.
KMID :
0869220100140010058
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Based on the operational criteria, 60.7% of pure AD patients and 58.8% of MD patients were responders to donepezil.